Results 21 to 30 of about 175,167 (244)

Asiatic acid alleviates Ang-II induced cardiac hypertrophy and fibrosis via miR-126/PIK3R2 signaling

Nutrition & Metabolism, 2021
Background Cardiac hypertrophy is an independent risk factor of many cardiovascular diseases. Studies have demonstrated that microRNA-126 (miR-126) was involved in angiogenesis during physiological and pathological process.
Haiyu Li, Xiaoxu Tian, Yongjuan Ruan, Junhui Xing, Zhe Meng   +4 more
doaj   +1 more source

Epigenetic Reader Bromodomain Containing Protein 2 Facilitates Pathological Cardiac Hypertrophy via Regulating the Expression of Citrate Cycle Genes

Frontiers in Pharmacology, 2022
The bromodomain and extra-terminal domain proteins (BETs) family serve as epigenetic “readers”, which recognize the acetylated histones and recruit transcriptional regulator complexes to chromatin, eventually regulating gene transcription.
Zhirong Lin, Zhenzhen Li, Zhen Guo, Yanjun Cao, Jingyan Li, Peiqing Liu, Zhuoming Li   +6 more
doaj   +1 more source

Cardiac Nonmyocytes in the Hub of Cardiac Hypertrophy [PDF]

Circulation Research, 2015
Cardiac hypertrophy is characterized by complex multicellular alterations, such as cardiomyocyte growth, angiogenesis, fibrosis, and inflammation. The heart consists of myocytes and nonmyocytes, such as fibroblasts, vascular cells, and blood cells, and these cells communicate with each other directly or indirectly via a variety of autocrine or ...
Takehiro, Kamo, Hiroshi, Akazawa, Issei, Komuro   +2 more
openaire   +2 more sources

Neutrophil-like cell membrane-coated siRNA of lncRNA AABR07017145.1 therapy for cardiac hypertrophy via inhibiting ferroptosis of CMECs

Molecular Therapy: Nucleic Acids, 2022
Cardiac microvascular dysfunction is associated with cardiac hypertrophy and can eventually lead to heart failure. Dysregulation of long non-coding RNAs (lncRNAs) has recently been recognized as one of the key mechanisms involved in cardiac hypertrophy ...
Pilong Shi, Minghui Li, Chao Song, Hanping Qi, Lina Ba, Yonggang Cao, Meitian Zhang, Yawen Xie, Jing Ren, Jiabi Wu, Ping Ren, Hongli Sun   +11 more
doaj   +1 more source

Adiponectin and Cardiac Hypertrophy in Acromegaly [PDF]

Advances in Clinical and Experimental Medicine, 2016
Adiponectin is an adipocytes-derived hormone which has been shown to possess insulin-sensitizing, antiatherogenic, and anti-inflammatory properties. In acromegaly, the data on adiponectin is contradictory. The relationship between adiponectin levels and cardiac parameters has not been studied.The aim of this study was to find out how adiponectin levels
Sabriye, Gurbulak, Fulya, Akin, Emrah, Yerlikaya, Guzin F, Yaylali, Senay, Topsakal, Halil, Tanriverdi, Beyza, Akdag, Bunyamin, Kaptanoglu   +7 more
openaire   +6 more sources

Enigma in cardiac hypertrophy [PDF]

Cardiovascular Research, 2010
The Enigma subfamily belongs to the PDZ- (for PSD-95, DLG, ZO-1) and LIM- (for LIN-11, Isl-1, MEC-3) encoding protein family. This family is composed of at least four different members: Enigma (also called PD-LIM7; LMP-1), Enigma homologue (ENH), ZASP/Cypher/Oracle, and LMP-4.
openaire   +2 more sources

A Disintegrin and Metalloprotease‐22 Attenuates Hypertrophic Remodeling in Mice Through Inhibition of the Protein Kinase B Signaling Pathway

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Severe cardiac hypertrophy can lead to cardiac remodeling and even heart failure in the end, which is a leading cause of cardiovascular disease–related mortality worldwide.
Lingyun Ren, Chuangyan Wu, Kai Yang, Shanshan Chen, Ping Ye, Jie Wu, Anchen Zhang, Xiaofan Huang, Ke Wang, Peng Deng, Xiangchao Ding, Manhua Chen, Jiahong Xia   +12 more
doaj   +1 more source

Mitochondria-associated endoplasmic reticulum membranes and cardiac hypertrophy: Molecular mechanisms and therapeutic targets

Frontiers in Cardiovascular Medicine, 2022
Cardiac hypertrophy has been shown to compensate for cardiac performance and improve ventricular wall tension as well as oxygen consumption. This compensatory response results in several heart diseases, which include ischemia disease, hypertension, heart
Yi Luan, Yage Jin, Pengjie Zhang, Hongqiang Li, Yang Yang   +4 more
doaj   +1 more source

Extracellular vesicular microRNAs and cardiac hypertrophy

Frontiers in Endocrinology
Cardiac hypertrophy is an adaptive response to pressure or volume overload such as hypertension and ischemic heart diseases. Sustained cardiac hypertrophy eventually leads to heart failure.
Hai Hu, Hai Hu, Xiulian Wang, Hui Yu, Hui Yu, Zhanli Wang   +5 more
doaj   +1 more source

Bellidifolin ameliorates isoprenaline-induced cardiac hypertrophy by the Nox4/ROS signalling pathway through inhibiting BRD4

Cell Death Discovery, 2023
To date, there is no effective therapy for pathological cardiac hypertrophy, which can ultimately lead to heart failure. Bellidifolin (BEL) is an active xanthone component of Gentianella acuta (G. acuta) with a protective function for the heart. However,
Dingyan Zhou, Weizhe Liu, Juanjuan Zhang, Yucui Dong, Jiangli Wu, Yu Zhang, Cheng Dai, Tingting Zhang, Gaoshan Yang, Yue Zhang, Aiying Li   +10 more
doaj   +1 more source